[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369682-105":59,"doc-detail-369682-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","oncolytic-virotherapy-and-tumor-microenvironment-modulation","Oncolytic virotherapy and tumor microenvironment modulation","","Oncolytic viruses (OVs) represent a transformative cancer therapy by selectively lysing tumors while sparing healthy tissues. Beyond direct cytolysis, OVs remodel the tumor microenvironment through increased immune infiltration, altered immunosuppressive signaling, and improved tumor antigen presentation. Given the complexity of tumor microenvironments and the emergence of resistance, combination approaches are often required. This review traces advances from naturally derived viruses to genetically engineered OVs, highlighting clinical progress and future directions for TME-targeted strategies and predictive biomarkers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/oncolytic-virotherapy-and-tumor-microenvironment-modulation/369682/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/oncolytic-virotherapy-and-tumor-microenvironment-modulation/369682.png","ImageObject",300,407,{"name":92,"@type":93},"Cipher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How do oncolytic viruses (OVs) work in cancer therapy beyond tumor cell lysis?","Question",{"text":112,"@type":113},"OVs reshape the tumor microenvironment by enhancing immune infiltration, disrupting immunosuppressive signals, and promoting tumor antigen presentation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why are oncolytic viruses often used in combination therapies?",{"text":117,"@type":113},"Tumor biology is complex and heterogeneous, and cancers can develop resistance, so combinations (e.g., immune checkpoint inhibitors, chemotherapy, or radiotherapy) are used to improve efficacy and overcome resistance.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the significance of T-VEC in oncolytic virotherapy?",{"text":121,"@type":113},"T-VEC is an FDA-approved HSV-derived OV modified for tumor-specific replication and expression of GM-CSF, which enhances anti-tumor immune responses, particularly in metastatic melanoma.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369682,1790211852,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},687208528416,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Clinical and Experimental Medicine (2025) 25:256 [https://doi.org/10.1007/s10238-025-01691-2](https://doi.org/10.1007/s10238-025-01691-2)  \nOncolytic virotherapy and tumor microenvironment modulation  \nSebastián Rivera‑Orellana1 · Jhommara Bautista1,2,3 · David Palacios‑Zavala1 · Sofía Ojeda‑Mosquera1 ·  \nAdriana Altamirano‑Colina1 · Malena Alcocer‑Veintimilla1 · Giuliana Parrales‑Rosales1 · Juan S. Izquierdo‑Condoy4 · Jorge Vásconez‑González4 · Esteban Ortiz‑Prado4 · Claire Muslin4 · Andrés López‑Cortés1  \nReceived: 26 February 2025 / Accepted: 14 April 2025 / Published online: 20 July 2025 © The Author(s) 2025  \nAbstract  \nOncolytic viruses (OVs) have emerged as a transformative approach in cancer therapy, offering tumor-specific lysis while sparing normal tissues. In addition to their direct cytolytic effects, OVs actively reshape the tumor microenvironment (TME) by enhancing immune infiltration, disrupting immunosuppressive signals, and promoting tumor antigen presentation. However, the complexity of the TME poses challenges, often necessitating combination therapies to improve OV efficacy and overcome tumor resistance. This review explores the evolution of oncolytic virotherapy, from the early use of naturally occurring viruses to the development of genetically engineered OVs. Among the most significant advancements, T-VEC, an FDA-approved herpesvirus, has been modified to express GM-CSF, enhancing immune activation in metastatic melanoma. Similarly, JX-594, a vaccinia virus, has been engineered for selective replication in tumor cells, demonstrating the potential of OVs to combine direct oncolysis with immune modulation. Other HSV-based OVs, such as HF10 and HSV1716, further highlight the ability of OVs to enhance immune cell infiltration and increase antigen presentation within the TME. Recent advances in tumor microenvironment remodeling have expanded OV therapeutic strategies. By converting immunologically“cold” tumors into “hot” tumors, OVs can overcome immune evasion through mechanisms such as enhanced antigen release, immune checkpoint inhibition, and metabolic reprogramming. To maximize therapeutic potential, researchers are developing genetically engineered OVs carrying immune-stimulatory transgenes, exploring synergistic combination therapies with immune checkpoint inhibitors, and utilizing nanoparticle-based delivery systems for improved precision. Additionally, novel OVs—including measles virus, Newcastle virus, Zika virus, and SARS-CoV-2—are being investigated for their unique ability to disrupt the TME and enhance anti-tumor immunity. Looking ahead, OV therapy will depend on optimizing TME-targeted strategies, improving viral delivery mechanisms, and identifying predictive biomarkers to personalize patient responses. Advances in viral engineering and immunomodulation hold the potential to revolutionize cancer treatment, offering more precise and effective therapeutic options. This review provides a comprehensive analysis of current progress in oncolytic virotherapy, emphasizing its potential to remodel the TME and improve clinical outcomes.  \nKeywords Oncolytic virotherapy · Tumor microenvironment · Cold tumor · Hot tumor · Virus  \n* Claire Muslin [claire.muslin@gmail.com](claire.muslin@gmail.com)  \n* Andrés López-Cortés[aalc84@gmail.com](aalc84@gmail.com)  \n1 Cancer Research Group (CRG), Faculty of Medicine, Universidad de Las Américas, Quito, Ecuador  \n2 Facultade de Ciencias, Universidade da Coruña, Campus de A Zapateira, A Coruña, Spain  \n3 Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain  \n4 One Health Research Group, Faculty of Health Sciences, Universidad de Las Américas, Quito, Ecuador  \nIntroduction  \nOncolytic viruses (OVs) have emerged as a promising class of cancer immunotherapeutics due to their ability to selectively infect and lyse tumor cells while stimulating an anti-tumor immune response. These viruses are genetically engineered to enhance their replication within ","cbCainanS8r64fBX","https://ap.wps.com/l/cbCainanS8r64fBX","pdf",1320395,12,"English","# Abstract\n# Introduction\n# Herpesvirus","[{\"question\":\"How do oncolytic viruses (OVs) work in cancer therapy beyond tumor cell lysis?\",\"answer\":\"OVs reshape the tumor microenvironment by enhancing immune infiltration, disrupting immunosuppressive signals, and promoting tumor antigen presentation.\"},{\"question\":\"Why are oncolytic viruses often used in combination therapies?\",\"answer\":\"Tumor biology is complex and heterogeneous, and cancers can develop resistance, so combinations (e.g., immune checkpoint inhibitors, chemotherapy, or radiotherapy) are used to improve efficacy and overcome resistance.\"},{\"question\":\"What is the significance of T-VEC in oncolytic virotherapy?\",\"answer\":\"T-VEC is an FDA-approved HSV-derived OV modified for tumor-specific replication and expression of GM-CSF, which enhances anti-tumor immune responses, particularly in metastatic melanoma.\"}]","Oncolytic virotherapy and tumor microenvironment modulation | PDF",1790184096,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/88543e5bf4c6084646637e32750af611.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f0eb4271684353333edae01e11103ef5.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c6de54f59b8ac930cd57022a3b94431f.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8e9e6b536c266039a3aa4d5598cfb766.webp",980,1301]